Quality-of-Life Instruments: Evaluation of the Impact of Psoriasis on Patients

Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco Medical Center, 515 Spruce Street, San Francisco, CA 94118, USA.
Dermatologic clinics (Impact Factor: 1.29). 04/2012; 30(2):281-91, ix. DOI: 10.1016/j.det.2011.11.006
Source: PubMed

ABSTRACT The negative impact of psoriasis on a patient's quality of life (QoL) is well documented in the literature. Patients often suffer poor self-esteem, difficulties in social interactions, and significant psychological distress. It is, therefore, critically important that a clinician evaluate the extent to which the disease impacts a patient's QoL. This chapter reviews several validated and reliable generic, dermatology-specific, and disease-specific QoL instruments useful in measuring the impact of psoriasis on patient's QoL. These QoL instruments can be especially helpful in identifying those patients who would most benefit from systemic or biologic therapy.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Psoriasis is a chronic skin disease that mainly affects the adult population and negatively affects the health-related quality of life (HRQoL). Objective To characterize the studies on HRQoL in people with psoriasis, 2003–2013. Methods Systematic review of the literature. We applied a research protocol with search terms, inclusion and exclusion criteria, and quality assessment of articles, by two researchers to ensure the completeness and reproducibility. The analysis was based on proportions, absolute frequencies, and the confidence intervals for proportions. Results The initial search identified 8684 studies, out of which 220 met the protocol established. Europe and North America accounted for the largest number of publications in HRQoL in people with psoriasis (86.4%), with 43.2% of studies seeking health profiles or HRQoL, and 46.8% to measure the impact of a therapeutic action on HRQoL. The measurement tools most used to study HRQoL in this group are the DLQI (Dermatology Life Quality Index) and SF-36. The largest proportion of studies did not show the severity state, and among the studies that did show it, the most common form was psoriasis vulgaris. Conclusion Despite the high prevalence of psoriasis in the world, few countries have published studies of the impact on HRQoL. The results found here demonstrate the importance and the need for the implementation of valid and reliable HRQOL measurement tools that can transcend traditional measurements of morbidity and disability, particularly in countries of America, where the development of research on this topic is scarce.
    03/2014; 21(1):35–41. DOI:10.1016/S0121-8123(14)70145-8
  • [Show abstract] [Hide abstract]
    ABSTRACT: Quality of life (QOL) is increasingly recognized as an important outcome measure in dermatology. Psoriasis has a great impact on QOL of patients, and has a strong effect on social relations, psychological status, and daily activities. This study describe and compare the impact of different grades of severity of psoriasis on QOL of patients in north of Iran.
    International journal of preventive medicine 09/2014; 5(9):1146-52.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Psoriatic Arthritis (PsA) is a heterogeneous disease that ranges from a mild form of oligoarthritis to destructive polyarthritis. The burden of disease can be severe and comparable to that of rheumatoid arthritis. Identifying predictors of worse outcome may improve the understanding of the underlying mechanisms of the disease and may guide therapeutic management at the individual level. Longitudinal cohort studies identified predictors of long-term outcomes such as joint damage, physical function and work disability in PsA. In general, male gender and lower burden of inflammation at presentation predict better outcome while a delay in diagnosis, disability and joint damage are associated with worse long term outcomes. Several HLA alleles also identify patients who are likely to sustain joint damage.
    Expert Review of Clinical Immunology 04/2014; DOI:10.1586/1744666X.2014.905741 · 3.34 Impact Factor